Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, DENTSPLY Sirona Inc (NASDAQ: XRAY) closed at $12.96 down -2.11% from its previous closing price of $13.24. In other words, the price has decreased by -$2.11 from its previous closing price. On the day, 3.02 million shares were traded. XRAY stock price reached its highest trading level at $13.33 during the session, while it also had its lowest trading level at $12.94.
Ratios:
For a deeper understanding of DENTSPLY Sirona Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2585310720 and an Enterprise Value of 4736310784. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.70 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 1.29 whereas that against EBITDA is 7.566.
Stock Price History:
The Beta on a monthly basis for XRAY is 0.97, which has changed by -0.4963078 over the last 52 weeks, in comparison to a change of 0.16333759 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $27.44, while it has fallen to a 52-week low of $12.16. The 50-Day Moving Average of the stock is -9.74%, while the 200-Day Moving Average is calculated to be -19.52%.
Shares Statistics:
For the past three months, XRAY has traded an average of 3.21M shares per day and 3248580 over the past ten days. A total of 199.30M shares are outstanding, with a floating share count of 198.20M. Insiders hold about 0.64% of the company’s shares, while institutions hold 101.84% stake in the company. Shares short for XRAY as of 1756425600 were 7641849 with a Short Ratio of 2.38, compared to 1753920000 on 7176058. Therefore, it implies a Short% of Shares Outstanding of 7641849 and a Short% of Float of 4.2700000000000005.
Dividends & Splits
According to the company, the forward annual dividend rate for XRAY is 0.64, from 0.64 in the trailing year. Against a Trailing Annual Dividend Yield of 0.04833837. The stock’s 5-year Average Dividend Yield is 1.75.
